Wave Life Sciences - WVE Stock Forecast, Price & News

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Stock Performance

Wave Life Sciences stock opened at $2.45 on Tuesday. The company has a 50 day moving average price of $2.75 and a 200-day moving average price of $2.34. Wave Life Sciences has a fifty-two week low of $1.16 and a fifty-two week high of $6.64. The company has a market capitalization of $150.06 million, a PE ratio of -1.15 and a beta of -0.51.

Wave Life Sciences (NASDAQ:WVE - Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Wave Life Sciences had a negative net margin of 275.31% and a negative return on equity of 558.73%. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $3.75 million. On average, analysts forecast that Wave Life Sciences will post -2.01 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on shares of Wave Life Sciences from $10.00 to $8.00 in a research note on Friday, May 13th.

Insider Activity

In related news, Director Ra Capital Management, L.P. purchased 9,480,052 shares of the firm's stock in a transaction dated Thursday, June 16th. The stock was purchased at an average price of $2.15 per share, with a total value of $20,382,111.80. Following the completion of the purchase, the director now owns 17,202,009 shares of the company's stock, valued at approximately $36,984,319.35. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 32.20% of the company's stock.